← All guides

Medical Device Development Project Timeline

Medical device development from concept to FDA clearance takes 2–5 years. Here's the project timeline covering design controls, verification, validation, and 510(k) or PMA submission.

Medical Device Development Project Timeline

The Problem: Medical Device Development Has Regulatory Constraints That Change Everything

Developing a medical device is not like developing a consumer product. FDA design controls (21 CFR Part 820) require that every design decision be documented, reviewed, and traceable from user needs through finished device specifications. Verification and validation testing cannot begin until design outputs are frozen. Clinical studies may be required before submission. And the submission itself — whether a 510(k), De Novo, or PMA — can take 3–12 months to reach FDA decision.

Teams that treat medical device development like software sprints discover the problem late: undocumented design decisions that cannot be reconstructed for the design history file, V&V testing that has to be repeated because design inputs changed, and clinical data that doesn't support the intended use claim. The regulatory constraint is not bureaucracy — it is the project structure. gantt-chart.io gives device teams a timeline that respects design control phases and keeps regulatory milestones visible from day one.

Prerequisites

  • Device concept defined; intended use and indications for use drafted
  • Regulatory pathway identified (510(k), De Novo, PMA, or exempt) based on risk classification
  • Predicate device identified if pursuing 510(k) clearance
  • Design control procedure in place per 21 CFR 820.30 or ISO 13485
  • Core team assembled: R&D, regulatory affairs, quality, clinical, manufacturing

Medical Device Development Project Timeline Gantt Chart Template

Phase 1: Concept and Feasibility (Months 1–4)

  • [ ] Document user needs and intended use; establish design input requirements
  • [ ] Conduct competitive analysis and freedom-to-operate review
  • [ ] Develop and test proof-of-concept prototypes; evaluate against design inputs
  • [ ] Perform preliminary risk analysis (ISO 14971); identify high-risk design elements
  • [ ] Prepare regulatory strategy memo; engage FDA via pre-submission (Q-Sub) if applicable
  • [ ] Complete feasibility report and design review gate (Design Review 1)

Phase 2: Design Development (Months 4–14)

  • [ ] Translate user needs into detailed design inputs (specifications)
  • [ ] Develop design outputs: engineering drawings, software requirements, manufacturing specs
  • [ ] Build and test alpha prototypes against design inputs
  • [ ] Select suppliers for critical components; establish quality agreements
  • [ ] Develop software architecture; initiate IEC 62304 software development lifecycle
  • [ ] Conduct Design Review 2: design inputs complete, design outputs in progress
  • [ ] Update risk management file; implement risk controls into design

Phase 3: Verification and Validation (Months 12–22)

  • [ ] Freeze design; establish design baseline for verification testing
  • [ ] Execute verification testing: performance, safety, EMC, biocompatibility, software validation
  • [ ] Build clinical trial units or pre-production units per design history file
  • [ ] Conduct usability validation studies (IEC 62366) with representative end users
  • [ ] Execute clinical study if required; collect and analyze clinical performance data
  • [ ] Conduct Design Review 3: V&V complete, design history file in final state

Phase 4: Regulatory Submission (Months 20–28)

  • [ ] Compile 510(k) or PMA submission; write substantial equivalence argument or clinical summary
  • [ ] Conduct internal pre-submission review; address gaps before filing
  • [ ] Submit to FDA; respond to any Requests for Additional Information (RAI) within 60 days
  • [ ] Prepare manufacturing site for FDA inspection if PMA; complete readiness assessment
  • [ ] Obtain FDA clearance or approval; resolve any conditions

Phase 5: Launch Preparation and Commercial Release (Months 26–32)

  • [ ] Transfer design to manufacturing; complete process validation (IQ, OQ, PQ)
  • [ ] Set up post-market surveillance system; define complaint handling procedures
  • [ ] Train sales, clinical support, and customer service teams
  • [ ] Complete labeling review; register device and establishment with FDA
  • [ ] Commercial launch; monitor post-market performance data

Common Pitfalls

  • Design inputs not locked before V&V begins: Verification tests a specific design. If design inputs change after V&V starts, testing must be repeated. Invest time in thorough design inputs upfront.
  • Software validation treated as an afterthought: Software is a medical device component subject to IEC 62304. Level B and C software requires full documentation of the software development lifecycle — this cannot be reconstructed retroactively.
  • Usability testing done once at the end: Formative usability studies should be conducted throughout development to catch use-error risks early. Summative validation at the end confirms, not discovers.
  • Clinical data strategy delayed: If the 510(k) requires clinical performance data, the clinical study adds 12–18 months. This decision must be made in Phase 1, not Phase 3.

What Good Looks Like

A well-managed device development program reaches FDA submission with a complete design history file, a risk management file with all residual risks accepted, full V&V test reports, and a clinical data package that directly supports the intended use claim. The submission receives no additional information requests because the quality of documentation anticipated every FDA question. First-in-human use occurs with trained clinical staff and a post-market surveillance plan already in place.